Group 1 - The event highlighted the importance of cross-border collaboration in enhancing the accessibility of advanced medical technologies in China, emphasizing the dual empowerment of multinational medical device companies and the local healthcare ecosystem [1] - Boston Scientific's local supply chain development has progressed significantly, with a strategic investment agreement signed in 2023, the establishment of a factory in 2024, and the production of four innovative products in 2025, showcasing the rapid pace of localization [2] - The Shanghai government has implemented supportive measures for foreign enterprises, creating a collaborative ecosystem that facilitates efficient product market entry, demonstrating a replicable service model for foreign medical device companies [2] Group 2 - The Shanghai Drug Administration has proactively engaged with Boston Scientific prior to the project's launch, enhancing the efficiency of registration and system verification through dedicated teams and policy initiatives [3] - The collaboration between Boston Scientific and its local partner, Xianruida, has resulted in the rapid development of the GX1 radiofrequency ablation product, highlighting the synergy between domestic efficiency and Boston Scientific's quality management [3] - Boston Scientific is expanding its localization efforts beyond production lines to include the domestic sourcing of raw materials and key components, aiming to meet clinical demands more swiftly through joint R&D with local partners [4] Group 3 - The Shanghai government plans to continue developing supportive policies to position the Lingang New Area as a significant hub in the global biomedicine industry [4] - The Shanghai Drug Administration will maintain its focus on regulatory support and service quality to help companies produce high-quality products for global markets [4] - Xianruida aims to advance the internationalization of Chinese innovative products, indicating a strategic direction for future growth [4]